|
Screening
|
Before implantation; every patient eligible for the study regardless of his/her participation in the trial
|
Checking of the inclusion/exclusion criteria
|
|
Implantation
|
Before inclusion in clinical trial
| |
|
Pretreatment examination
|
Before randomization
|
Clinical control of implant site; informed consent
|
|
Baseline: second-stage surgery and insertion of first abutment
|
90 ± 14 days after implantation
|
Tissue sampling (control punch biopsy)
|
|
Photo documentation
|
|
X-ray control
|
|
PICF sampling
|
7, 14, 21, and 28 (±1) days after insertion of the first, second, and third abutment
|
PICF sampling
|
|
Plaque Index (PI)
|
|
Gingival Index (GI)
|
|
Probing depth (PD)
|
|
Bleeding on probing (BOP)
|
|
Tissue sampling and insertion of second and third abutments
|
2–5 days after the last PICF sampling around the first, second, and third abutment
|
Tissue sampling (ring biopsy)
|
